Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) remains a life-limiting condition with a major impact on the ability to lead a normal life. Although existing therapies may improve the outlook in some patients there remains a major unmet need to develop more effective therapies in this condition. There have been significant advances in our understanding of the genetic, cell and molecular basis of PAH over the last few years. This research has identified important new targets that could be explored as potential therapies for PAH. In this review we discuss whether further exploitation of vasoactive agents could bring additional benefits over existing approaches. Approaches to enhance smooth muscle cell apotosis and the potential of receptor tyrosine kinase inhibition are summarised. We evaluate the role of inflammation, epigenetic changes and altered glycolytic metabolism as potential targets for therapy, and whether inherited genetic mutations in PAH have revealed druggable targets. The potential of cell based therapies and gene therapy are also discussed. Potential candidate pathways that could be explored in the context of experimental medicine are identified.

• Publication year

  2013

• Venue

  Pulmonary Circulation

• Publication date

  2013-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.4103/2045-8932.109940PMID 23662201PMCID 3641734
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Riociguat for the treatment of pulmonary hypertension

  2014cited by this paper
• Dynamin-Related Protein 1–Mediated Mitochondrial Mitotic Fission Permits Hyperproliferation of Vascular Smooth Muscle Cells and Offers a Novel Therapeutic Target in Pulmonary Hypertension

  2012cited by this paper
• Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries

  2012cited by this paper
• Pulmonary Arterial Hypertension in Patients Treated by Dasatinib

  2012cited by this paper
• Gremlin Plays a Key Role in the Pathogenesis of Pulmonary Hypertension

  2012cited by this paper
• Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension

  2012cited by this paper
• Cicletanine in pulmonary arterial hypertension (PAH): Results from a phase 2 randomized placebo-controlled trial

  2012cited by this paper
• Modern age pathology of pulmonary arterial hypertension.

  2012cited by this paper
• Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension.

  2012cited by this paper
• Activin–like kinase–3 activity is important for kidney regeneration and reversal of fibrosis

  2012cited by this paper
• Therapeutic potential for HDAC inhibitors in the heart.

  2012cited by this paper
• Lung ¹⁸F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension.

  2012cited by this paper
• Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension.

  2012cited by this paper
• Selective Class I Histone Deacetylase Inhibition Suppresses Hypoxia-Induced Cardiopulmonary Remodeling Through an Antiproliferative Mechanism

  2012cited by this paper
• A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

  2012cited by this paper
• The monocrotaline model of pulmonary hypertension in perspective.

  2012cited by this paper
• TREM-1 interaction with the LPS/TLR4 receptor complex.

  2011cited by this paper
• Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart.

  2011cited by this paper
• Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension.

  2011cited by this paper
• The Oral Histone Deacetylase Inhibitor ITF2357 Reduces Cytokines and Protects Islet β Cells In Vivo and In Vitro

  2011cited by this paper
• Histone Deacetylase Inhibitors for Treating a Spectrum of Diseases Not Related to Cancer

  2011cited by this paper
• Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats.

  2011cited by this paper
• Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival.

  2011cited by this paper
• Riociguat for the treatment of pulmonary hypertension

  2011cited by this paper
• [Effect of apelin on vasodilatation of isolated pulmonary arteries in rats is concerned with the nitric oxide pathway].

  2011influential reference
• Bone morphogenetic protein receptor II regulates pulmonary artery endothelial cell barrier function.

  2011cited by this paper
• Peptide-directed highly selective targeting of pulmonary arterial hypertension.

  2011cited by this paper
• Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities.

  2011cited by this paper
• Pharmocoepigenetics: a new approach to predicting individual drug responses and targeting new drugs

  2011cited by this paper
• Expression of mutant BMPR-II in pulmonary endothelial cells promotes apoptosis and a release of factors that stimulate proliferation of pulmonary arterial smooth muscle cells

  2011cited by this paper
• Induction of Vascular GTP-Cyclohydrolase I and Endogenous Tetrahydrobiopterin Synthesis Protect Against Inflammation-Induced Endothelial Dysfunction in Human Atherosclerosis

  2011cited by this paper
• Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis.

  2011cited by this paper
• Targeted gene delivery of BMPR2 attenuates pulmonary hypertension

  2011cited by this paper
• Efficacy and safety of sirolimus in lymphangioleiomyomatosis.

  2011cited by this paper
• Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle’s cycle

  2011cited by this paper
• Disruption of the Apelin-APJ System Worsens Hypoxia-Induced Pulmonary Hypertension

  2011cited by this paper
• Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats.

  2011cited by this paper
• Efficacy and safety of sirolimus in lymphangioleiomyomatosis.

  2011cited by this paper
• Emergence of Fibroblasts with a Proinflammatory Epigenetically Altered Phenotype in Severe Hypoxic Pulmonary Hypertension

  2011cited by this paper
• A novel murine model of severe pulmonary arterial hypertension.

  2011cited by this paper
• Mesenchymal Stromal Cells Expressing Heme Oxygenase‐1 Reverse Pulmonary Hypertension

  2011cited by this paper
• Safety of sapropterin dihydrochloride (6r–bh4) in patients with pulmonary hypertension

  2011cited by this paper
• Rodent models of pulmonary hypertension: harmonisation with the world health organisation’s categorisation of human PH

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Role of epidermal growth factor inhibition in experimental pulmonary hypertension.

  2010cited by this paper
• Epigenetic Attenuation of Mitochondrial Superoxide Dismutase 2 in Pulmonary Arterial Hypertension: A Basis for Excessive Cell Proliferation and a New Therapeutic Target

  2010cited by this paper
• [Protective and therapeutic effect of apelin on chronic hypoxic pulmonary hypertension in rats].

  2010cited by this paper
• Identification of a Lysosomal Pathway Regulating Degradation of the Bone Morphogenetic Protein Receptor Type II

  2010cited by this paper
• Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats

  2010cited by this paper
• Interleukin-6 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension

  2010cited by this paper
• Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors.

  2010cited by this paper
• Elevated Levels of Inflammatory Cytokines Predict Survival in Idiopathic and Familial Pulmonary Arterial Hypertension

  2010cited by this paper
• Formation of Plexiform Lesions in Experimental Severe Pulmonary Arterial Hypertension

  2010cited by this paper
• Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.

  2010cited by this paper
• A Dosing/Cross‐Development Study of the Multikinase Inhibitor Sorafenib in Patients With Pulmonary Arterial Hypertension

  2010cited by this paper
• Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension.

  2010cited by this paper
• Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension

  2010cited by this paper
• Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension.

  2010cited by this paper
• Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension

  2010cited by this paper
• The oral histone deacetylase inhibitor ITF 2357 reduces cytokines and protects islet beta-cells in vivo and in vitro

  2010cited by this paper
• Basic Science of Pulmonary Arterial Hypertension for Clinicians: New Concepts and Experimental Therapies

  2010cited by this paper
• Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study

  2010cited by this paper
• Epigenetic regulation of the cardiovascular system: introduction to a review series.

  2010cited by this paper
• Prevalence of anti-endothelial cell antibodies in idiopathic pulmonary arterial hypertension

  2010cited by this paper
• Mesenchymal stem cell-based prostacyclin synthase gene therapy for pulmonary hypertension rats

  2010cited by this paper
• Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats.

  2010cited by this paper
• Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization.

  2009cited by this paper
• The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle

  2009cited by this paper
• Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22α‐targeted overexpression of the serotonin transporter

  2009cited by this paper
• Cellular and molecular basis of pulmonary arterial hypertension.

  2009cited by this paper
• Inflammation, growth factors, and pulmonary vascular remodeling.

  2009cited by this paper
• Interleukin-6 Overexpression Induces Pulmonary Hypertension

  2009cited by this paper
• Therapeutic targets in pulmonary arterial hypertension.

  2009cited by this paper
• First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension

  2009cited by this paper
• Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure.

  2009cited by this paper
• Altered Bone Morphogenetic Protein and Transforming Growth Factor-β Signaling in Rat Models of Pulmonary Hypertension: Potential for Activin Receptor-Like Kinase-5 Inhibition in Prevention and Progression of Disease

  2009cited by this paper
• Phase 2 study of sodium phenylbutyrate in ALS

  2009cited by this paper
• Pulmonary apelin levels and effects in rats with hypoxic pulmonary hypertension.

  2009influential reference
• Acute Pulmonary Hypertension

  2009cited by this paper
• Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation

  2009cited by this paper
• Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension.

  2009cited by this paper
• Bone Morphogenetic Protein (BMP) and Activin Type II Receptors Balance BMP9 Signals Mediated by Activin Receptor-like Kinase-1 in Human Pulmonary Artery Endothelial Cells*

  2009cited by this paper
• Stress Doppler Echocardiography in Relatives of Patients With Idiopathic and Familial Pulmonary Arterial Hypertension: Results of a Multicenter European Analysis of Pulmonary Artery Pressure Response to Exercise and Hypoxia

  2009cited by this paper
• Structure-function studies for the panacea, valproic acid.

  2009cited by this paper
• Antifibroblast antibodies from systemic sclerosis patients bind to α-enolase and are associated with interstitial lung disease

  2009cited by this paper
• Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension

  2008cited by this paper
• A quantitative analysis of kinase inhibitor selectivity

  2008cited by this paper
• Acute vasodilator effects of Rho-kinase inhibitors in neonatal rats with pulmonary hypertension unresponsive to nitric oxide.

  2008cited by this paper
• Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.

  2008cited by this paper
• Emerging concepts and translational priorities in pulmonary arterial hypertension.

  2008cited by this paper
• Cicletanine for the treatment of pulmonary arterial hypertension.

  2008cited by this paper
• Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension.

  2008cited by this paper
• Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: potential for rescue.

  2008cited by this paper
• Autologous transplantation of bone marrow–derived endothelial progenitor cells attenuates monocrotaline-induced pulmonary arterial hypertension in rats

  2008cited by this paper
• Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling

  2008influential reference
• A Long-Acting and Highly Selective Prostacyclin Receptor Agonist Prodrug, 2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), Ameliorates Rat Pulmonary Hypertension with Unique Relaxant Responses of Its Active Form, {4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)

  2008cited by this paper
• Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4.

  2008cited by this paper
• Molecular pathogenesis of pulmonary arterial hypertension.

  2008cited by this paper
• Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics

  2008cited by this paper
• An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension.

  2008cited by this paper

• An Overview of Hypertension: Pathophysiology, Risk Factors, and Modern Management.

  2025cites this paper
• Lactate dehydrogenase-induced DNA Topoisomerase 1 is a novel regulator of smooth muscle cell proliferation and remodeling in pulmonary arterial hypertension

  2025cites this paper
• Zinc-mediated Inhibition of Soluble Epoxide Hydrolase Promotes Pulmonary Hypertension.

  2024cites this paper
• Expression of soluble guanylate cyclase (sGC) and its ability to form a functional heterodimer are crucial for reviving the NO-sGC signaling in PAH.

  2024cites this paper
• Parathyroid Hormone Related Protein (PTHrP)-Associated Molecular Signatures in Tissue Differentiation and Non-Tumoral Diseases

  2023cites this paper
• Cross-talk between TSC2 and the extracellular matrix controls pulmonary vascular proliferation and pulmonary hypertension

  2022cites this paper
• New Insight in HDACs: Potential Therapeutic Targets for the Treatment of Atherosclerosis

  2022cites this paper
• Anticipated pharmacological role of Aviptadil on COVID-19

  2021influential citation
• TSC2-extracellular matrix crosstalk controls pulmonary vascular proliferation and pulmonary hypertension

  2021cites this paper
• Idiopathic Pulmonary Arterial Hypertension in the Pediatric Age Group

  2021cites this paper
• Epigenetic targets for oligonucleotide therapies of pulmonary hypertension

  2020cites this paper
• Differential effects of integrin-linked kinase inhibitor Cpd22 on severe pulmonary hypertension in male and female rats

  2020cites this paper
• Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVID-19

  2020cites this paper
• Epigenetic Targets for Oligonucleotide Therapies of Pulmonary Arterial Hypertension

  2020cites this paper
• O-GlcNAc Transferase Regulates Angiogenesis in Idiopathic Pulmonary Arterial Hypertension

  2019cites this paper
• Dioscin: A diverse acting natural compound with therapeutic potential in metabolic diseases, cancer, inflammation and infections

  2018cites this paper
• Paeonol regulates hypoxia‐induced proliferation of pulmonary artery smooth muscle cells via EKR 1/2 signalling

  2018cites this paper
• Pharmacological Inhibition of mTOR Kinase Reverses Right Ventricle Remodeling and Improves Right Ventricle Structure and Function in Rats

  2017cites this paper
• Dimethyl Fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways

  2017cites this paper
• Nanocarriers as treatment modalities for hypertension

  2017cites this paper
• A systematic review of genetic mutations in pulmonary arterial hypertension

  2017cites this paper
• PCPA protects against monocrotaline-induced pulmonary arterial remodeling in rats: potential roles of connective tissue growth factor

  2017cites this paper
• BMP type II receptor as a therapeutic target in pulmonary arterial hypertension

  2017cites this paper
• Effects of an endothelin receptor antagonist, Macitentan, on right ventricular substrate utilization and function in a Sugen 5416/hypoxia rat model of severe pulmonary arterial hypertension

  2017influential citation
• Molecular Basis of Nitrative Stress in the Pathogenesis of Pulmonary Hypertension.

  2017cites this paper
• The Effects of Chronic Hypoxia on Inflammation and Pulmonary Vascular Function

  2016cites this paper
• Oxidative and nitrosative signalling in pulmonary arterial hypertension - Implications for development of novel therapies.

  2016cites this paper
• [Pulmonary (Arterial) Hypertension].

  2016cites this paper
• Evaluation of the potential synergism of imatinib‐related poly kinase inhibitors using growth factor stimulated proteoglycan synthesis as a model response

  2016cites this paper
• Pulmonal (arterielle) Hypertonie

  2016cites this paper
• Investigative Therapies in Pulmonary Arterial Hypertension

  2015cites this paper
• Microvessel Mechanobiology in Pulmonary Arterial Hypertension: Cause and Effect

  2015cites this paper
• Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension: The PHACeT Trial.

  2015cites this paper
• O-Linked &bgr;-N-Acetylglucosamine Transferase Directs Cell Proliferation in Idiopathic Pulmonary Arterial Hypertension

  2015cites this paper
• Emerging Roles for Histone Deacetylases in Pulmonary Hypertension and Right Ventricular Remodeling (2013 Grover Conference series)

  2015cites this paper
• Novel investigational therapies for treating pulmonary arterial hypertension

  2015cites this paper
• Epigenetic targets for novel therapies of lung diseases.

  2015cites this paper
• 1 1 Utility of induced pluripotent stem cell derived endothelial cells as pulmonary arterial hypertension models

  2015cites this paper
• Pathophysiology and Treatment of Pulmonary Arterial Hypertension

  2015cites this paper
• Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension The PHACeT Trial

  2015cites this paper
• Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension The PHACeT Trial

  2015cites this paper
• NPY/Y1 receptor‐mediated vasoconstrictory and proliferative effects in pulmonary hypertension

  2014cites this paper
• THE EFFECTS OF A NOVEL ENDOTHELIN RECEPTOR ANTAGONIST, MACITENTAN, ON RIGHT VENTRICULAR SUBSTRATE UTILIZATION AND FUNCTION IN A SUGEN5416/HYPOXIA RAT MODEL OF SEVERE PULMONARY ARTERY HYPERTENSION

  2014influential citation
• Revisiting the concept of hepatosplenic schistosomiasis and its challenges using traditional and new tools.

  2014cites this paper
• Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Genetics of pulmonary hypertension

  2014cites this paper
• Phenotype in Pulmonary Hypertension Proinflammatory/Profibrotic Macrophage Adventitial Fibroblasts Induce a Distinct

  2014cites this paper
• Is pulmonary hypertension a metabolic disease?

  2014cites this paper
• Adventitial Fibroblasts Induce a Distinct Proinflammatory/Profibrotic Macrophage Phenotype in Pulmonary Hypertension

  2014cites this paper
• Cellular interplay in pulmonary arterial hypertension: implications for new therapies.

  2014cites this paper
• New horizons in pulmonary arterial hypertension therapies

  2013cites this paper
• O-Linked β-N-Acetylglucosamine Transferase Directs Cell Proliferation in Idiopathic Pulmonary Arterial Hypertension

  year unknowncites this paper